AIP
CMPI

Ameritas Investment Partners’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Ameritas Investment Partners’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-430
Closed -$5K – 3321
2021
Q1 		$5K Hold
430
– – ﹤0.01% 3019
2020
Q4 		$6K Hold
430
– – ﹤0.01% 2959
2020
Q3 		$5K Buy
+430
New +$5.51K ﹤0.01% 2995

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Ameritas Investment Partners's CMPI Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2021, closing a stake of 430 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in CMPI in Q3 2020 and held it in 3 quarters. The position peaked at $6K in Q4 2020. 34 funds tracked by Wall St. Rank hold CMPI as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 430 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $5K.
  • Ameritas Investment Partners first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Ameritas Investment Partners's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $6K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.